Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,404.00
Bid: 11,500.00
Ask: 12,496.00
Change: 0.00 (0.00%)
Spread: 996.00 (8.661%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Debenhams Raised After Strong Report

Fri, 17th Apr 2015 08:58

LONDON (Alliance News) - The following shares received analyst recommendations Friday morning:
---------
FTSE 100
----------
CANACCORD RAISES SMITHS GROUP PRICE TARGET TO 1410 (1390) PENCE - 'HOLD'
----------
EXANE BNP RAISES SMITHS GROUP PRICE TARGET TO 1150 (1050) PENCE - 'NEUTRAL'
----------
NOMURA RAISES SMITHS GROUP PRICE TARGET TO 1400 (1320) PENCE - 'NEUTRAL'
----------
JPMORGAN RAISES SMITHS GROUP PRICE TARGET TO 1520 (1310) PENCE - 'OVERWEIGHT'
----------
EXANE BNP RAISES WEIR GROUP PRICE TARGET TO 1925 (1500) PENCE
----------
EXANE BNP RAISES WEIR GROUP TO 'NEUTRAL' ('UNDERPERFORM')
----------
EXANE BNP CUTS GKN TO 'NEUTRAL' ('OUTPERFORM') - TARGET 380 PENCE
----------
CREDIT SUISSE RAISES WHITBREAD PRICE TARGET TO 6200 (5300) PENCE - 'OUTPERFORM'
----------
CANACCORD RAISES KINGFISHER PRICE TARGET TO 334 (300) PENCE - 'HOLD'
----------
CANACCORD RAISES DIAGEO PRICE TARGET TO 1515 (1465) PENCE - 'SELL'
----------
JPMORGAN RAISES UNILEVER PLC PRICE TARGET TO 2900 (2750) PENCE - 'UNDERWEIGHT'
----------
Liberum Raises Unilever Price Target To 2,400p From 2,310p, Reiterates Sell
----------
JPMORGAN RAISES SABMILLER PRICE TARGET TO 4000 (3650) PENCE - 'OVERWEIGHT'
----------
UBS RAISES SABMILLER PRICE TARGET TO 3600 (3500) PENCE - 'NEUTRAL'
----------
BERENBERG RAISES SABMILLER PRICE TARGET TO 3920 (3700) PENCE - 'BUY'
----------
Berenberg Raises SABMiller Price Target To 3,920p From 3,700p, Reiterates Buy
----------
DAVY INITIATES ROYAL MAIL WITH 'UNDERPERFORM' - TARGET 380 PENCE
----------
GOLDMAN RAISES MEGGITT PRICE TARGET TO 592 (573) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES BAE SYSTEMS PRICE TARGET TO 611 (577) PENCE - 'BUY'
----------
DEUTSCHE BANK RAISES ASTRAZENECA PRICE TARGET TO 4850 (4800) PENCE - 'HOLD'
----------
DEUTSCHE BANK RAISES SHIRE PRICE TARGET TO 5900 (5700) PENCE - 'BUY'
----------
FTSE 250
----------
EXANE BNP RAISES MELROSE INDUSTRIES TARGET TO 315 (300) PENCE - 'OUTPERFORM'
----------
CANACCORD CUTS PETRA DIAMONDS PRICE TARGET TO 220 (230) PENCE - 'BUY'
----------
EXANE BNP CUTS VESUVIUS PRICE TARGET TO 515 (540) PENCE - 'OUTPERFORM'
----------
EXANE BNP RAISES SPIRAX-SARCO PRICE TARGET TO 3550 (3500) PENCE - 'NEUTRAL'
----------
EXANE BNP CUTS ROTORK PRICE TARGET TO 2600 (2610) PENCE - 'NEUTRAL'
----------
BARCLAYS CUTS ROTORK TO 'EQUAL WEIGHT' ('OVERWEIGHT')
----------
EXANE BNP RAISES IMI PRICE TARGET TO 1150 (1100) PENCE - 'UNDERPERFORM'
----------
EXANE BNP RAISES HALMA PRICE TARGET TO 800 (780) PENCE - 'OUTPERFORM'
----------
EXANE BNP RAISES SPECTRIS TO 'NEUTRAL' ('UNDERPERFORM') - TARGET 2375 (1850) PENCE
----------
BARCLAYS RAISES SPECTRIS PRICE TARGET TO 2535 (2065) PENCE - 'OVERWEIGHT'
----------
CREDIT SUISSE RAISES JUPITER FUND PRICE TARGET TO 430 (378) PENCE - 'NEUTRAL'
----------
MORGAN STANLEY RAISES PLAYTECH PRICE TARGET TO 1030 (960) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS CARILLION PRICE TARGET TO 305 (330) PENCE - 'NEUTRAL'
----------
PANMURE RAISES PROVIDENT FINANCIAL PRICE TARGET TO 3000 (2700) PENCE - 'HOLD'
----------
SOCGEN RAISES DEBENHAMS PRICE TARGET TO 80 (67) PENCE - 'HOLD'
----------
UBS RAISES DEBENHAMS PRICE TARGET TO 90 (85) PENCE - 'BUY'
----------
CITIGROUP RAISES DEBENHAMS TO 'BUY' ('NEUTRAL') - TARGET 95 (75) PENCE
----------
BARCLAYS RAISES MORGAN ADVANCED MATERIALS TARGET TO 350 (305) PENCE - 'EQUALWEIGHT'
----------
BARCLAYS RAISES LAIRD PRICE TARGET TO 370 (315) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES IMI PRICE TARGET TO 1380 (1340) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES HALMA PRICE TARGET TO 715 (650) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS CUTS DOMINO PRINTING TO 'EQUAL WEIGHT' ('OVERWEIGHT')
----------
BARCLAYS RAISES DOMINO PRINTING PRICE TARGET TO 915 (730) PENCE
----------
BARCLAYS RAISES RENISHAW PRICE TARGET TO 2825 (2425) PENCE - 'OVERWEIGHT'
----------
GOLDMAN RAISES QINETIQ PRICE TARGET TO 208 (204) PENCE - 'NEUTRAL'
----------
BARCLAYS RAISES QINETIQ TO 'OVERWEIGHT' ('EQUAL WEIGHT') - TARGET 220 (210) PENCE
----------
BARCLAYS INITIATES MONEYSUPERMARKET WITH 'OVERWEIGHT' - TARGET 315 PENCE
----------
TRADERS: HSBC RAISES PENNON GROUP PRICE TARGET TO 970 (960) PENCE
----------
GOLDMAN CUTS ULTRA ELECTRONICS PRICE TARGET TO 1833 (2011) PENCE - 'NEUTRAL'
----------
GOLDMAN RESUMES COBHAM WITH 'NEUTRAL' - TARGET 329 PENCE
----------
GOLDMAN CUTS PETROFAC TO 'BUY' ('CONVICTION BUY LIST') - TARGET 1130 PENCE
----------
GOLDMAN RAISES HUNTING TO 'CONVICTION BUY' ('BUY') - TARGET 709 (622) PENCE
----------
MAIN MARKET AND AIM
----------
CANACCORD RAISES ONESAVINGS BANK TO 'BUY' ('HOLD') - TARGET 316 (290) PENCE
----------
JPMORGAN CUTS MOTHERCARE PRICE TARGET TO 235 (239) PENCE - 'OVERWEIGHT'
----------
JPMORGAN INITIATES URBAN & CIVIC WITH 'NEUTRAL' - TARGET 300 PENCE
----------
Cantor Fitzgerald Raises Chariot Oil & Gas Price Target To 20p From 12p, Reiterates Buy
----------
BARCLAYS RAISES OXFORD INSTRUMENTS PRICE TARGET TO 1000 (860) PENCE
----------
BARCLAYS RAISES OXFORD INSTRUMENTS TO 'OVERWEIGHT' ('EQUAL WEIGHT')
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
24 Oct 2023 17:08

LONDON MARKET CLOSE: FTSE 100 shakes off midday losses after US data

(Alliance News) - The FTSE 100 closed in the green on Tuesday following positive private sector data out of the US, despite figures closer to home showing a weaker UK private sector and rising unemployment.

Read more
24 Oct 2023 11:06

AstraZeneca says US accepts self-administered flu vaccine for review

(Alliance News) - AstraZeneca PLC on Tuesday said the US health watchdog has approved a review for its FluMist Quadrivalent self-administered flu vaccine, for which the drugmaker is seeking a green light.

Read more
23 Oct 2023 17:50

AstraZeneca celebrates drug trial results for cancer indications

(Alliance News) - AstraZeneca PLC on Monday said new drugs, developed in partnership with Daiichi Sankyo Co Ltd, showed positive results in patients with solid tumours, lung and breast cancer.

Read more
23 Oct 2023 17:08

LONDON MARKET CLOSE: Stocks largely down on Middle East hostilities

(Alliance News) - Stock prices in London closed largely lower on Monday, as investors were unable to shake off concerns surrounding the conflict in the Middle East, while developments in the US bond market added to the drama.

Read more
23 Oct 2023 08:45

TOP NEWS: AstraZeneca says Enhertu approved by European Commission

(Alliance News) - AstraZeneca PLC on Monday said its Enhertu treatment has been approved by the European Commission to treat adult lung cancer patients.

Read more
23 Oct 2023 07:46

LONDON BRIEFING: Keller expects higher profit; Upland rejects approach

(Alliance News) - Stocks in London are set to open slightly higher on Monday, as risk sentiment improves after a difficult period for markets last week.

Read more
18 Oct 2023 09:04

AstraZeneca drug Solaris approved in China as NMOSD treatment

(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder

Read more
17 Oct 2023 12:06

LONDON MARKET MIDDAY: European markets uneasy but FTSE 100 outperforms

(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.

Read more
16 Oct 2023 08:34

TOP NEWS: AstraZeneca's cancer drug gets priority review from US FDA

(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.

Read more
4 Oct 2023 12:14

IN BRIEF: AstraZeneca's Forxiga drug shows positive results in trial

AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.

Read more
3 Oct 2023 16:55

LONDON MARKET CLOSE: Stocks red as rate rise fears continue to grow

(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
3 Oct 2023 08:36

TOP NEWS: AstraZeneca settles Nexium and Prilosec litigation

(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.

Read more
3 Oct 2023 07:41

LONDON BRIEFING: Greggs sales rise; boohoo cuts revenue outlook

(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.

Read more
3 Oct 2023 07:24

AstraZeneca agrees to settle most Nexium, Prilosec claims

(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.